Table 6. Immunophenotyping results for the patients when Matutes Score was not available

 

Patient  number

Ly 109/L

CD 45+  %

CD

3+

%

CD 3-

CD56+

%

CD

19+

%

CD

20+

%

К %

λ%

К/λ

Other characteristics

Conclusion

6

10.3

++  20

56

34

9

4

70

30

2.3

Plasma cells

Myeloma or Plasma cell leukemia

7

3.6

++  18

51

15

34

34

97

3

32.3

Lymphocyte,  Plasmocyte, Ig M

Waldenström disease

8

50.9

++  89

8

86

5

5

59

41

1.4

CD 3-CD16+

NK Proliferation

9

35.2

±   65

0

 

0

0

 

 

 

c MPO-, CD 34+, HLA-DR+, CD 117-, CD 33-

Acute leukemia

10

70.0

±  80

50

 

0

0

 

 

 

c MPO-, c CD3+, HLA-DR+, CD 5+, CD 7+

T-cell ALL

11

20.5

± 15

8

-

5

 

 

 

 

cMPO+, CD 34+, HLA-DR+, CD 33+

AML

12

7.4

± 20

15

 

28

 

 

 

 

Myeloblast/ cMPO+, CD 34+, HLA-DR+, CD 33+

AML-M2

 

Abbreviation: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Ly, lymphocytes.